Jangada Mines Plc (JAN), a Brazil-focused natural resource development company, announced the appointment of Hugo de Salis to the Board as a Non-Executive Director with immediate effect.
Mr. de Salis brings over 30 years’ experience in financial services. He began his career at Schroders Unit Trust Ltd and then later at J.P. Morgan Investment Management. After a period at Weber Shandwick, he founded St Brides Partners Ltd, advising listed companies on investor relations with a focus on natural resources.
Comment: It is interesting to read that our Hugo has done so much in his career, over and above founding PR/IR company St Brides. One would imagine his presence will bolster the ongoing breakout for JAN shares.
WeCap PLC: A Retail Look at a Company Suddenly in Focus
Kropz Plc (KRPZ), an emerging African phosphate producer and developer, announced a trading update for the period to 30 September 2025 and that Kropz Elandsfontein (Pty) Ltd. Elandsfontein produced 87,496 tonnes of phosphate concentrate in Q3 2025, representing a 17% increase compared to the previous quarter. Sales for the period totalled 72,408 tonnes, a 28% increase quarter on quarter. The quarter closed with a record production month in September 2025, during which 34,070 tonnes of phosphate concentrate were produced. The mine remains in its trial production phase.
Comment: KRPZ has distinguished itself in the recent past by being a phosphate company which is closest to production, something which still the case. At least this means that the share price is firm within the range and is likely to remain so off the back of the latest announcement.
Trellus Health® plc (TRLS), a healthcare company delivering Trellus Elevate®, announced it has entered into a unsecured loan agreement with the Company’s long standing substantial shareholder, Icahn School of Medicine at Mount Sinai, with a principal amount of US$600,000. The proceeds from the Loan Note will support the continued execution of the Company’s commercial strategy and extend its near-term cash runway to late January 2026. The Company remains in active discussions regarding a potential equity fundraising to extend the cash runway further. While these discussions are at an advanced stage, there is no guarantee that they will be concluded successfully or within the required timeframe.
Comment: At one stage this year, and for quite an extended period it appears that TRLS could be the next big healthcare prospect. Now one might say that in the wake of the latest loan and with the clock ticking on further funding, things are perhaps not quite as rosy.
OptiBiotix Health plc (OPTI, a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes provided an overview and update on its SweetBiotix® product range for new and existing investors. OPTI said, “The Company has made a breakthrough in improving the manufacturing process of its SweetBiotix products. By using a new enzyme, rather than an enzyme extract, the Company is able to achieve substantially higher yields of a purer, more concentrated, better tasting product with lower ingredient and production costs. These are significant benefits when producing at large scale. This new enzyme works on both mogrosides and stevia glycosides allowing the generation of multiple SweetBiotix products using the same enzyme creating products with a wide sweetness range.”
Comment: You have to hand it to OPTI, it carries on regardless as if we were living in a parallel universe where there is no Ozempic, Wegovy or Mounjaro. That is a bit like ignoring smartphones, Wi-Fi and Bluetooth. But hey.
Upland Resources Ltd (UPL) announced that it has entered into a Strategic Partnership and Framework Agreement with a US Corporation, Lost Soldier Oil and Gas II Master Series LLC. The parties have executed a mutually agreed framework agreement, establishing a commercial bilateral investment, intended farm-in arrangements, and a broader operational partnership. The execution of this Framework Agreement and bilateral investment represents a significant milestone for Upland, strengthening the Company’s financial and technical capabilities as it develops its interests in Southeast Asia.
Comment: After all the hype, especially on social media, UPL has proved itself to be one of the stealth share price risers of the year, and not perhaps even from the news / breakthroughs that the market was necessarily expecting.
Alien Metals Limited (UFO), a minerals exploration and development company, reported that its joint venture partner, West Coast Silver Limited (ASX: WCE) has announced further encouraging silver observations from its Phase 2 diamond drilling programme at the Elizabeth Hill Silver Project in the Pilbara region of Western Australia. This brings the total to 13 holes drilled, of which nine holes have visible silver mineralisation, confirmed by pXRF Belinda Murray, Executive Director of Alien, commented: “West Coast Silver’s work continues to validate our position in Elizabeth Hill. These latest results confirm the presence of additional shallow, high-grade silver and point to a system that extends beyond the historically mined areas. It is a strong outcome for this phase of work and reinforces the growth potential of the project.”
Comment: The new CEO Belinda Murray has everything to play for in terms of getting the UFO show back on the road, and the share price on the front foot. News such as today’s regarding Elizabeth Hill is certainly a step in the right direction.
Roquefort Therapeutics (ROQ), the Main Market listed biotech company, advised that Dr Darrin Disley, Interim Managing Director, has purchased 5m shares at 1.70p for a consideration of £85,000, to take his percentage in the company to 4.46%.
Comment: Anyone choosing to spend 85 grand on shares so close to Christmas and the Budget must be either very keen, or loaded, or perhaps both. The good Doctor’s purchase underlines how ROQ shares do give the impression of being under-rated.
MTI Wireless Edge Ltd (MWE), the technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announced its financial results for the nine-month period ended 30 September 2025. 12% increase in revenues for the Period to $37.8m (9 months to 30 September 2024: $33.7m). 21% improvement in profit from operations to $4.2m (9 months to 30 September 2024: $3.5m). MWE said: “This quarter delivered record revenues and profitability, positioning the business for a strong full-year performance. The Company has also been highly cash-generative, with net cash provided by operating activities of $4.0m in the first nine months of 2025 compared with $3.1m for the full 12 months of 2024. Overall, this represents a very satisfying performance to date.”
Comment: The main reason for including MWE in the RNS Hotlist today is that historically the company has not exactly been sizzling in terms of promoting itself, its performance, or its prospects. Perhaps this comment will mark a turning point?
ImmuPharma PLC (IMM), the specialist drug discovery and development company, announced an update on P140 partnership discussions. In the Corporate Update notification of 23 October 2025, ImmuPharma advised that it had started to engage with a number of potential partners on P140, and that the Company’s stated objective was to complete a deal by the end of 2025. IMM said “Based on the engagements with potential partners to date, the Board now expects the completion of any partnership deal to extend beyond the end of 2025, with our aim being to move to completion of a deal as soon as practicable in 2026. The current cash runway now extends well into Q4 2026. The Company reaffirms it has no intention to raise further funds and will look to further strengthen its cash position as a result of deals with potential commercial partners.”
Comment: It is a shame that IMM boxed itself into a corner as far as getting partners by the end of the year, something which was not really necessary. Indeed, it means that even reassurance over the cash runway has not prevented a knee-jerk markdown in the shares today.
Ananda Pharma plc (AQSE: ANA), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announced that it has that it has today published a circular to shareholders including a notice of general meeting in connection with the proposed withdrawal of admission of the Company’s ordinary shares of £0.002 each to trading on the AQSE Growth Market.
Comment: It is all the more disappointing that Melissa Sturgess’s company is going private given how much effort was obviously made to promote the company and its ground-breaking offering. This is especially the case given how promising the newsflow has been this year.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
